tetano
Editor, Senior Moderator
Sci Rep
. 2020 Dec 29;10(1):22418.
doi: 10.1038/s41598-020-80120-8.
In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients
Joonho Park[SUP] 1 [/SUP], Hyeyoon Kim[SUP] 1 [/SUP], So Yeon Kim[SUP] 2 [/SUP], Yeonjae Kim[SUP] 3 [/SUP], Jee-Soo Lee[SUP] 4 [/SUP], Kisoon Dan[SUP] 1 [/SUP], Moon-Woo Seong[SUP] 5 [/SUP], Dohyun Han[SUP] 6 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over forty million patients worldwide. Although most coronavirus disease 2019 (COVID-19) patients have a good prognosis, some develop severe illness. Markers that define disease severity or predict clinical outcome need to be urgently developed as the mortality rate in critical cases is approximately 61.5%. In the present study, we performed in-depth proteome profiling of undepleted plasma from eight COVID-19 patients. Quantitative proteomic analysis using the BoxCar method revealed that 91 out of 1222 quantified proteins were differentially expressed depending on the severity of COVID-19. Importantly, we found 76 proteins, previously not reported, which could be novel prognostic biomarker candidates. Our plasma proteome signatures captured the host response to SARS-CoV-2 infection, thereby highlighting the role of neutrophil activation, complement activation, platelet function, and T cell suppression as well as proinflammatory factors upstream and downstream of interleukin-6, interleukin-1B, and tumor necrosis factor. Consequently, this study supports the development of blood biomarkers and potential therapeutic targets to aid clinical decision-making and subsequently improve prognosis of COVID-19.
. 2020 Dec 29;10(1):22418.
doi: 10.1038/s41598-020-80120-8.
In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients
Joonho Park[SUP] 1 [/SUP], Hyeyoon Kim[SUP] 1 [/SUP], So Yeon Kim[SUP] 2 [/SUP], Yeonjae Kim[SUP] 3 [/SUP], Jee-Soo Lee[SUP] 4 [/SUP], Kisoon Dan[SUP] 1 [/SUP], Moon-Woo Seong[SUP] 5 [/SUP], Dohyun Han[SUP] 6 [/SUP]
Affiliations
- PMID: 33376242
- DOI: 10.1038/s41598-020-80120-8
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over forty million patients worldwide. Although most coronavirus disease 2019 (COVID-19) patients have a good prognosis, some develop severe illness. Markers that define disease severity or predict clinical outcome need to be urgently developed as the mortality rate in critical cases is approximately 61.5%. In the present study, we performed in-depth proteome profiling of undepleted plasma from eight COVID-19 patients. Quantitative proteomic analysis using the BoxCar method revealed that 91 out of 1222 quantified proteins were differentially expressed depending on the severity of COVID-19. Importantly, we found 76 proteins, previously not reported, which could be novel prognostic biomarker candidates. Our plasma proteome signatures captured the host response to SARS-CoV-2 infection, thereby highlighting the role of neutrophil activation, complement activation, platelet function, and T cell suppression as well as proinflammatory factors upstream and downstream of interleukin-6, interleukin-1B, and tumor necrosis factor. Consequently, this study supports the development of blood biomarkers and potential therapeutic targets to aid clinical decision-making and subsequently improve prognosis of COVID-19.